hbsag

RG7834 (RO 7020322) is a highly selective and orally bioavailable inhibitor of HBV, targeting HBsAg, HBeAg, and HBV DNA with IC50s of 2.8 nM, 2.6 nM, and 3.2 nM, respectively, in dHepaRG Cells.

Oleana-2,12-dien-28-oic acid is an HBsAg and HBeAg inhibitor that significantly inhibits HBV deoxyribonucleic acid (HBV-DNA) replication in HepG2.2.15 cells, making it relevant for the study of hepatitis B virus infection.

HBF-0259 is an inhibitors of hepatitis B virus surface antigen (HBsAg) secretion with an EC50 of 11.3 μM and a CC50 value of >50 μM in HepG2.2.15 cells. HBF-0259 had a EC50 of approximately 1.5 microM in a secondary, HBV-expressing cell line, with a concentration that exhibited 50% cytotoxicity of >50 microM. The equilibrium concentration of HBF-0259 in aqueous solution at physiological pH was 15 to 16 microM; the selective index was thus >9.

ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).

1, 2, 3, 4, 6-Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) and gallic acid from Pistacia lentiscus have antimutagenic and antioxidant activities. 2. 1, 2, 3, 4, 6-Penta-O-galloyl-beta-D-glucose (PGG) possesses potent anti-proliferative and anti-invasive effects, it also has inhibition of inducible nitric oxide synthase and cyclooxygenase-2 activity. 3. PGG may serve as a model for the development of new types of anti-diabetic and anti-metabolic syndrome therapeutics. 4. 1, 2, 3, 4, 6-Penta- O -galloyl-β- d -glucose has vasodilatory and anti-inflammatory effects, it dilates vascular smooth muscle and suppresses the vascular inflammatory process via endothelium-dependent nitric oxide (NO) cGMP signaling. 5. 1, 2, 3, 4, 6-Penta-O-galloyl-beta-D-glucose can decrease the level of extracellular hepatitis B virus (HBV) (IC5, 1. microg ml) in a dose-dependent manner, it also can reduce the HBsAg level by 25% at a concentration of 4 microg ml; the gallate structure of PGG may play a critical role in the inhibition of anti-HBV activity, suggests that PGG could be a candidate for developing an anti-HBV agent. 6. 1, 2, 3, 4, 6-Penta-O-galloyl-β-D-glucose has anti-parasitic activity, displays an EC5 value of 67 μM, at least 6.6-fold more effective than the standard drug benznidazole against trypomastigote forms of T. cruzi.

ZINC20451377 is a small molecule compound that binds with high affinity to the hepatitis B surface antigen (HBsAg), with a dissociation constant (Kd) of 65.3 nM. It reduces HBsAg levels and HBV particle secretion in HBV cell culture models.

AB-161 is an orally active destabilizer of HBV RNA and an inhibitor of PAPD5 7, primarily targeting the liver. It treats hepatitis B virus (HBV) infection by reducing hepatitis B surface antigen (HBsAg) levels, exhibiting an EC50 value of 2.2 nM for HBsAg. AB-161 is applicable in HBV infection research.

BA-AZT1 acts as an inhibitor of HBV polymerase (HBV polymerase) and sodium taurocholate cotransporting polypeptide (NTCP). It hinders the secretion of viral capsid proteins HBsAg and HBeAg, with IC50 values of 0.65 µM and 13.42 µM, respectively, and inhibits HBV DNA replication with an IC50 of 0.70 µM.

The nucleocapsid of the hepatitis B virus is covered by an envelope of HBV surface antigen (HBsAg), which has the common, group-specific determinant a. The four major subtypes of HBsAg, adw, adr, ayw and ayr, are generated, and they have been proposed to

Nirtetralin suppresses HBsAg and HBeAg expression.

Destruxin B2 is a cyclic hexadepsipeptide mycotoxin that has been found in M. anisopliae and has antiviral, insecticidal, and phytotoxic activities.1,2,3 It inhibits secretion of hepatitis B virus surface antigen (HBsAg) by Hep3B cells expressing hepatitis B virus (HBV) DNA (IC50 = 1.3 μM).1 Destruxin B2 is toxic to Sf9 insect cells in an electric cell-substrate impedance sensing (ECIS) test with a 50% inhibitory concentration (ECIS50) value of 92 μM.4 It is also phytotoxic to B. napus leaves.3 |1. Yeh, S.F., Pan, W., Ong, G.-T., et al. Study of structure-activity correlation in destruxins, a class of cyclodepsipeptides possessing suppressive effect on the generation of hepatitis B virus surface antigen in human hepatoma cells. Biochem. Biophys. Res. Commun. 229(1), 65-72 (1996).|2. Male, K.B., Tzeng, Y.-M., Montes, J., et al. Probing inhibitory effects of destruxins from Metarhizium anisopliae using insect cell based impedance spectroscopy: Inhibition vs chemical structure. Analyst 134(7), 1447-1452 (2009).|3. Buchwaldt, L., and Green, H. Phytotoxicity of destruxin B and its possible role in the pathogenesis of Alternaria brassicae. Plant Pathol. 41(1), 55-63 (1992).

HBV-IN-24 (compound (2 S, 6S)-1a) is a potent inhibitor of HBV. HBV-IN-24 is a strong inhibitor of HBV DNA (EC50: 0.6 nM), HBsAg (EC50: 0.6 nM) and HBeAg (EC50: 4.6 nM). antiviral effect and was able to improve neurotoxicity.

HBV-IN-12 is a potent inhibitor of hepatitis B surface antigen (HBsAg).

HBV-IN-9 (example 20) is a potent inhibitor of HBsAg (HBV surface antigen) with an IC50 of 10 nM and also inhibits HBV DNA replication with an IC50 of 0.15 nM.

HBV-IN-11 is a potent inhibitor of HBsAg secretion (EC50: 0.46 μM).

(5S,8R)-HBV-IN-10, an isomer of compound 6 (WO2021204258A1), is a potent inhibitor of hepatitis B surface antigen (HBsAg) with an EC50 range of 0.1 μM to 1 μM.

HBV-IN-10 is an isomer of compound 6 (WO2021204258A1). Compound 6 is a potent inhibitor of hepatitis B surface antigen (HBsAg) (0.1 μM < EC50 ≤ 1 μM).

HBV-IN19 has inhibitory effects on hepatitis B virus (HBV) infection. HBV-IN19 inhibits HBsAg secretion and or production and can be used in the study of HBV infection (e.g. chronic HBV infection).

HBV-IN-12 is a potent inhibitor of hepatitis B surface antigen (HBsAg) with an EC50 range of 0.001 μM to 0.05 μM and demonstrates anti-HBV DNA activity with an EC50 range of 0.001 μM to 0.02 μM.

HBV-IN19 TFA inhibits the secretion and or production of HBsAg and has an inhibitory effect on hepatitis B virus (HBV) infection and can be used in studies of HBV infection, including chronic HBV infection.

HBV-IN-31, a potent inhibitor of covalently closed circular DNA (cccDNA), demonstrates significant anti-HBV activity by inhibiting cell growth and exhibiting an IC50 value of 0.13 µM for HBsAg.

HBV-IN-32, a potent inhibitor of covalently closed circular DNA (cccDNA), exhibits significant anti-Hepatitis B Virus (HBV) activity by achieving an IC50 of 0.14 µM against HBsAg. Additionally, it impedes cell growth.

Hepatitis B Virus Pre-S Region (120-145) is a preS2 peptide that effectively blocks the attachment of single-chain Fv fragment (scFv) or IgG to recombinant Hepatitis B surface antigen (r-HBsAg) [1].

HBV Seq2 aa:28-39, a Hepatitis B surface antigen (HBsAg) peptide, specifically binds to Major Histocompatibility Complex (MHC) class I molecules, as evidenced in sources [1] [2].